Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Acetylsalicylic acid + pseudoephedrine is a fixed-dose combination of two active pharmaceutical ingredients: acetylsalicylic acid (commonly known as aspirin), a nonsteroidal anti-inflammatory drug (NSAID) with analgesic, antipyretic, and anti-inflammatory properties, and pseudoephedrine, an alpha-adrenergic agonist that acts as a nasal decongestant. This combination is used for the symptomatic treatment of pain (such as headache or sore throat), fever, and nasal congestion associated with upper respiratory tract infections like the common cold or flu. Acetylsalicylic acid works by inhibiting cyclooxygenase enzymes COX-1 and COX-2 to reduce prostaglandin synthesis, thereby decreasing inflammation, pain sensitivity, and fever. Pseudoephedrine acts primarily on alpha adrenergic receptors to cause vasoconstriction in the nasal mucosa, reducing swelling and congestion[1][2][5][8]. Developers: Bayer
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Acetylsalicylic acid + pseudoephedrine.